Using cell culture and xenograft models, Sun et al. showed that GBM cell proliferation was reduced when the cells were treated with an Hsp90 inhibitor, NMS-E973, by upregulating the proapoptotic Bcl-2 member PUMA in a p53-dependent way. Here, TP53 is linked to glioblastoma.